Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Prostate cancer

Response prediction with HSD3B1

Nature Reviews Urology volume 14, page 699 (2017)Cite this article

Subjects

Access through your institution
Buy or subscribe

“We previously discovered that a common germline variant of HSD3B1 encodes a gain-of-function in 3β-HSD1 that essentially increases the rate-limiting step of dihydrotestosterone synthesis from extragonadal precursor steroids,” explains Nima Sharifi from the Cleveland Clinic, Ohio, USA, senior author of both studies. “We also previously showed that patients harbouring this variant have worse outcomes than those who do not when receiving androgen deprivation therapy [(ADT)] for PSA recurrence after prostatectomy or metastatic disease.”

In the first of the two new studies, the researchers investigated associations between HSD3B1 genotype and outcomes in men who had PSA recurrence after definitive radiotherapy for localized prostate cancer treated with ADT, as effects of the HSD3B1 variant in these patients were unknown.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Almassi, N. et al. HSD3B1 and response to a nonsteroidal CYP17A1 inhibitor in castration-resistant prostate cancer. JAMA Oncol. http://dx.doi.org/10.1001/jamaoncol.2017.3159 (2017)

  2. Hearn, J. W. et al. Association of HSD3B1 genotype with response to androgen-deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer. JAMA Oncol. http://dx.doi.org/10.1001/jamaoncol.2017.3164 (2017)

Download references

Authors
  1. Clemens Thoma
    View author publications

    Search author on:PubMed Google Scholar

Related links

Related links

Related links in Nature Research

Stuchbery, R. et al. Androgen synthesis in prostate cancer: do all roads lead to Rome? Nat. Rev. Urol. 14, 49–58 (2017)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Thoma, C. Response prediction with HSD3B1. Nat Rev Urol 14, 699 (2017). https://doi.org/10.1038/nrurol.2017.192

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrurol.2017.192

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing